Patent: 8,809,010
✉ Email this page to a colleague
Summary for Patent: 8,809,010
Title: | Method for prophylactic treatment of alzheimer\'s disease using inhibitors of glutaminyl cyclase and glutamate cyclases |
Abstract: | Provided herein are methods for treating and preventing neurodegenerative disease in a mammal by administering an inhibitor of glutaminyl cyclase (QC). Neurodegenerative diseases treatable or preventable according to methods described herein include mild cognitive impairment (MCI), Alzheimer\'s disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia. |
Inventor(s): | Hoffmann; Torsten (Halle/Saale, DE), Schilling; Stephan (Halle/Saale, DE), Niestroj; Andre J. (Sennewitz, DE), Demuth; Hans-Ulrich (Halle/Saale, DE), Heiser; Ulrich (Halle/Saale, DE), Buchholz; Mirko (Halle/Saale, DE) |
Assignee: | Probiodrug AG (Halle (Saale), DE) |
Application Number: | 12/506,823 |
Patent Claims: | see list of patent claims |
Details for Patent 8,809,010
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Jubilant Hollisterstier Llc | N/A | positive skin test control-histamine | Injection | 103891 | 03/13/1924 | ⤷ Try a Trial | 2023-05-05 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2023-05-05 |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2023-05-05 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2023-05-05 |
Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 11/23/2004 | ⤷ Try a Trial | 2023-05-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |